Key result
Extracellular vesicles show therapeutic promise for Parkinson's disease by delivering molecules across the blood-brain barrier.
Why the study?
Parkinson's disease incidence is increasing rapidly, and extracellular vesicles, while involved in pathophysiology, can cross the blood-brain barrier and be explored as therapeutic delivery vehicles.
Extracellular vesicles represent a promising cell-free therapeutic approach and drug delivery vehicle for Parkinson's disease due to their ability to cross the blood-brain barrier.
May support preclinical EV research in Parkinson's; leaves open clinical translation pending controlled trials.
Globally, the incidence of Parkinson’s disease (PD) is increasing faster than other neurodegenerative disorders. Neuropathologically, PD is characterized by the loss of dopaminergic neurons in the substantia nigra pars compacta due to the accumulation of aggregates of misfolded α-synuclein (α-Syn) in the cytoplasm of these neurons, forming Lewy bodies. Extracellular vesicles (EVs) are associated with the spread of α-Syn to different brain areas. However, at the same time that these EVs contribute to the pathophysiology of PD, they can also be explored as therapeutic, serving as a vehicle to deliver specific molecules, since these vesicles can easily cross the blood-brain barrier. Thus, this review summarizes the recent progress in EVs as a therapeutic strategy for PD, focusing on their delivery to the brain, and discusses the potential challenges and future directions in this field.
No takes yet. Share an insight, caveat, or question.
Teixeira et al. (2023) conducted a review in Parkinson's disease. Extracellular vesicles was evaluated. Extracellular vesicles show promise as a therapeutic strategy for Parkinson's disease by serving as vehicles to deliver specific molecules across the blood-brain barrier.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: